CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY

a technology of synthetic peptides and conjugates, which is applied in the field of conjugates comprised of polymer and synthetic peptides derived, can solve the problems of limiting the bioavailability of therapeutic agents, affecting the biological activity of therapeutic agents, so as to increase the biological half-life of synthetic peptides
US20100016225A1Inactive Publication Date: 2010-01-21TRIMERIS
12 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
TRIMERIS
Publication Date
2010-01-21
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to application Ser. No. 10 / 671,282, filed Sep. 24, 2003, which claims the benefit of Provisional Application No. 60 / 414,439, filed Sep. 27, 2002, both of which are incorporated by reference herein in their entireties.FIELD OF THE INVENTION

[0002] The present invention relates to conjugates comprised of polymer and synthetic peptides derived from Human Immunodeficiency Virus (HIV) gp41. More particularly, the present invention comprises a conjugate formed by operably binding to a polymer no less than two molecules of synthetic peptide comprising an amino acid sequence derived from either the HR1 region or the HR2 region of HIV-1 gp41.BACKGROUND OF THE INVENTION

[0003] It is now well known that cells can be infected by HIV through a process by which fusion occurs between the cellular membrane and the viral membrane. The generally accepted model of this process is that the viral envelope glycoprotein complex (gp1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More